Are the High Serum Interleukin-6 and Vascular Endothelial Growth Factor Levels Useful Prognostic Markers in Aggressive Non-Hodgkin Lymphoma Patients?

ÜSKÜDAR TEKE, HAVA; GÜNDÜZ, EREN; Akay, Olga; BAL, CENGİZ; Gulbas, Zafer

doi:10.4274/tjh.2013.0325

Are the High Serum Interleukin-6 and Vascular Endothelial Growth Factor Levels Useful Prognostic Markers in Aggressive Non-Hodgkin Lymphoma Patients?

ÜSKÜDAR TEKE H., GÜNDÜZ E., Akay O. M., BAL C., Gulbas Z.

TURKISH JOURNAL OF HEMATOLOGY, cilt.32, sa.1, ss.21-28, 2015 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 32 Sayı: 1
Basım Tarihi: 2015
Doi Numarası: 10.4274/tjh.2013.0325
Dergi Adı: TURKISH JOURNAL OF HEMATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
Sayfa Sayıları: ss.21-28
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Objective: Pro-inflammatory and pro-angiogenic cytokines play an important role in the pathogenesis of lymphoma, and recent studies have shown that cytokines can be used as prognostic markers. Non-Hodgkin lymphoma (NHL) patients with high levels of serum interleukin-6 (s-IL6) and serum vascular endothelial growth factor (s-VEGF) have poor prognosis and shorter survival time. We aimed to determine pre-treatment levels of s-IL6 and s-VEGF and their relation with known prognostic markers, especially International Prognostic Index (IPI) scores, and to examine their effects on overall survival in newly diagnosed, untreated aggressive NHL patients.